ADMA Biologics (ADMA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.09 (+0.46%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of ADMA Biologics (ADMA)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Key Insights

Critical company metrics and information
  • Share Price

    $19.86
  • Market Cap

    $4.69 Billion
  • Total Outstanding Shares

    236.39 Million Shares
  • Total Employees

    624
  • Dividend

    No dividend
  • IPO Date

    October 17, 2013
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.admabiologics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-1.54 Million
Net Cash Flow From Operating Activities$25.03 Million
Net Cash Flow$-1.54 Million
Net Cash Flow From Operating Activities, Continuing$25.03 Million
Net Cash Flow From Investing Activities, Continuing$-1.10 Million
Net Cash Flow From Financing Activities$-25.47 Million
Net Cash Flow From Investing Activities$-1.10 Million
Net Cash Flow From Financing Activities, Continuing$-25.47 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$35.91 Million
Operating Income/Loss$39.64 Million
Cost Of Revenue$60.18 Million
Net Income/Loss$35.91 Million
Diluted Average Shares$244.80 Million
Nonoperating Income/Loss$-2.89 Million
Income Tax Expense/Benefit$840000.00
Gross Profit$59.66 Million
Costs And Expenses$83.09 Million
Research and Development$412000.00
Operating Expenses$20.02 Million
Income/Loss From Continuing Operations Before Tax$36.75 Million
Basic Earnings Per Share$0.15
Net Income/Loss Attributable To Parent$35.91 Million
Benefits Costs and Expenses$83.09 Million
Revenues$119.84 Million
Income/Loss From Continuing Operations After Tax$35.91 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Average Shares$234.57 Million
Depreciation and Amortization$1.94 Million
Diluted Earnings Per Share$0.15
Selling, General, and Administrative Expenses$18.56 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0.00
Assets$390.62 Million
Accounts Payable$16.02 Million
Inventory$171.80 Million
Equity$231.89 Million
Noncurrent Liabilities$113.84 Million
Liabilities$158.73 Million
Current Assets$318.19 Million
Current Liabilities$44.89 Million
Noncurrent Assets$72.42 Million
Intangible Assets$485000.00
Equity Attributable To Parent$231.89 Million
Other Non-current Assets$18.25 Million
Other Current Liabilities$28.87 Million
Liabilities And Equity$390.62 Million
Other Current Assets$146.39 Million
Fixed Assets$53.69 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to ADMA Biologics (ADMA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.